Physician profile
Devendra D Patel
NPI 1992146864
$4,933.29
in general payments reported to CMS, 2019-2025
23 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $246 · 2021: $803 · 2022: $1,352 · 2023: $1,091 · 2024: $666 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,156.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,001.31 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $660.11 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $576.48 | 2019-2024 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $324.77 | 2019-2025 | Lifevest |
| Gilead Sciences, INC. | $260.52 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $241.24 | 2019-2025 | Lokelma, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.39 | 2019-2025 | Jardiance |
| Abbvie INC. | $235.82 | 2022-2025 | |
| Pfizer INC. | $235.48 | 2022-2025 | |
| Ucb, INC. | $226.32 | 2022-2023 | Cimzia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.59 | 2022-2025 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $182.22 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.15 | 2021-2025 | |
| Lexicon Pharmaceuticals, INC. | $98.11 | 2023 | Inpefa |
| Amgen INC. | $72.09 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $69.23 | 2025 | Paradise Ultrasound Renal Denervation System |
| Boston Scientific Corporation | $55.45 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $34.84 | 2023 | Verquvo |
| Takeda Pharmaceuticals U.S.A., INC. | $31.76 | 2022 | |
| Csl Behring | $28.01 | 2023 | Kcentra |
| Nestle Healthcare Nutrition INC. | $19.10 | 2021 | |
| Advanced Respiratory, INC | $18.96 | 2021 | |
| Baxter Healthcare | $18.34 | 2023 | Hillrom - Life 2000 Ventilation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devendra Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.